Objective: To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender.
A GE-RELATED MACULAR DEgeneration (AMD) is the leading cause of blindness among Europeandescended people older than 65 years. [1] [2] [3] [4] [5] [6] While individual studies have arrived at estimates of both early AMD and more severe stages of the disease (advanced AMD), the numbers of persons identified with AMD, and the numbers of individuals in the oldest age groups are frequently small, yielding somewhat unstable estimates.
Recent research has demonstrated that the likelihood of vision loss from AMD can be reduced in individuals with high-dose vitamin supplementation 7 and can be reduced with laser photocoagulation and photodynamic therapy in others with neovascular (NV) forms of the disease. [8] [9] [10] [11] However, the reduction in visual loss using these treatments for persons with geographic atrophy (GA) and for most persons with NV AMD is limited. Policy planners require solid estimates of disease prevalence to determine the likely benefit of these and future therapies. This study was undertaken to determine more accurately the prevalence of intermediate and advanced AMD in the United States by pooling findings from large population-based studies that have been conducted over the last 2 decades and applying the prevalence rates to the US population. Furthermore, we have estimated the expected increase in AMD in the future.
METHODS

DEFINITIONS
We focused on obtaining accurate estimates of the prevalence of NV AMD and GA as well as the presence of large drusen (ie, those Ն125 µm). Given the large overlap of pigmentary changes with large drusen, and data that show that large drusen are associated with an almost 6% risk of developing advanced AMD over 5 years in the involved eye (Ronald Klein, MD, MPH, written communication, September 16, 2002) , and because it had been measured in all of the populations, we chose to look at large drusen as a manifestation of intermediate AMD. Therefore, the definitions used for this study are as follows.
EPIDEMIOLOGY
Age-related macular degeneration is defined as that named AMD by the International ARM Study Group, and includes the following 2 groups 12 : (1) those with GA, which is a discrete area of retinal depigmentation at least 175 µm in diameter with a sharp border and visible choroidal vessels in the absence of NV AMD in the same eye; and (2) those with NV AMD, which is serous or hemorrhagic detachment of either the retinal pigment epithelium or sensory retina, the presence of subretinal fibrous tissue, or minimal subretinal fibrosis and widespread retinal pigment epithelial atrophy. Or it is any AMD that represents the presence of GA or NV AMD in either eye.
Subjects were classified as having GA if either eye had GA. Similarly, subjects were classified as having NV AMD if either eye had NV, so some individuals were counted in both categories of AMD. Therefore, estimates for any AMD will be lower than the combined total of estimates for NV AMD and GA.
Large drusen were defined as drusen 125 µm or larger in diameter in the macula (defined as a region 3000 µm in diameter centered on the foveola) in either or both eyes.
INCLUSION CRITERIA FOR STUDIES
To be included in the present research, the studies contributing data had to (1) be population based, (2) provide data on the conditions being studied; and (3) use a standard photographic grading system for determining the prevalence of AMD and drusen. Since these studies were conducted when no preventive treatments were available for AMD, all known studies meeting these criteria (both published and unpublished) were included. These include the Baltimore Eye Survey, Baltimore, Md 13 Table 1 ). The Baltimore Eye Survey enrolled 5308 black and white persons (75% of the intended population), 19% of whom had no gradable photographs for AMD. 13 The Barbados Eye Study enrolled 4314 black persons (84% of the intended population), 17% of whom had no photographs gradable for AMD. 14 The Beaver Dam Eye Study enrolled 4926 subjects (83% of the intended population, 4896 of whom were white), 2% of whom had no gradable photographs for AMD. 15 The Blue Mountains Eye Study enrolled 3654 white persons (82% of the eligible population), 2% of whom had no gradable photographs for AMD. 16 The Rotterdam Study had 6872 persons visit the study center (67% of the intended population), 0.9% of whom had no gradable photographs for AMD. 17 The Salisbury Eye Evaluation Project enrolled 65% of the eligible population (all persons were Ն65 years), 2% of whom had no gradable photographs. 19 The Melbourne Vision Impairment Project enrolled 4345 (92% of the eligible population) of 4744 persons. 18
STATISTICAL ANALYSIS
The investigators from each study provided us with the number of individuals with gradable photographs in at least 1 eye and the number found to have NV AMD, GA, or any AMD in at least 1 eye, and at least 1 large druse in 1 or both eyes stratified by gender and race for groups aged 40 through 44, 45 through 49, 50 through 54, 55 through 59, 60 through 64, 65 Years study conducted 1985-1988 1988-1992 1988-1990 1992-1994 1990-1993 1993-1995 1991-1998 through 69, 70 through 74, 75 through 79, 80 through 84, 85 through 89 years, and 90 years and older.
Age-Specific Prevalence Estimates
The age-specific prevalence proportions were derived in 2 steps. First, pooled prevalence proportions were estimated for each race/ ethnic-, gender-, and age-specific stratum using minimum variance linear estimation. Stratum-specific proportions from each study were transformed using a logarithm odds transformation, and proportion variances were estimated assuming the binomial distribution. Second, logistic regression models were fit to the pooled prevalence proportions using the midpoint of each age interval as the independent variable. Models were fit separately by gender for GA, NV AMD, any AMD, and the presence of drusen in white persons. Prevalence rates for drusen in the Beaver Dam Eye Study were significantly higher (Figure 1) than those found in the other studies and, thus, were excluded from the pooled prevalence estimates for drusen in white persons. Age and race/ethnicity effects in the models were tested using the Wald 2 test statistic. Odds ratios for gender differences were based on Mantel-Haenszel 2 tests for the 2ϫ2 tables of observed rates, adjusting for age and the study effect.
Owing to the few cases of AMD in black persons, models were only fit for any AMD and drusen. Age-specific prevalence rates for NV AMD and GA in black persons were estimated by applying a constant factor to the modeled agespecific rates for any AMD. These factors (0.73 for NV AMD and 0.27 for GA in women, and 0.59 for NV AMD and 0.41 for GA in men) were based on the observed proportion of all individuals with AMD who were identified with either GA or NV AMD in either eye. Prevalence rates for NV AMD, GA, any AMD, and drusen in Hispanic persons and other races/ethnicities were assumed to be similar to rates found in black persons.
Estimates of Prevalence in the United States
The number of cases of AMD in the United States in each race/ ethnicity, gender, and age category were generated by applying the modeled prevalence rate for each year of age to the 2000 US Census population and summing across the age range for each 5-year age category. Projected estimates were derived in the same manner, using US Census middle-series population projections for 2020. Stratum-specific US prevalence rates were computed by dividing the total number of estimated cases for each stratum by the stratum-specific US population. Esti- mates for AMD in Western Europe and Australia were based on applying the age-and gender-specific rates found in white persons to their respective populations 40 years and older.
RESULTS
WHITE PERSONS
Pooled data for European-descended individuals from the Baltimore Eye Survey, the Blue Mountains Eye Study, the Beaver Dam Eye Study, the Rotterdam Study, the Melbourne Vision Impairment Project, and for those older than 65 years from the Salisbury Eye Evaluation Project found a strong age-related increase in the prevalence of large drusen, GA, NV AMD, and any AMD (Figure 1 and Figure 2 ). There were dramatic increases in rates for both men and women older than 80 years, with models showing a highly significant quadratic term for age. Of white females in the 50-through 54-year-old range, 0.20% had AMD vs 1.52% of those aged 70 through 74 years and 16.39% of those older than 80 years ( Table 2) . Geographic atrophy was slightly less prevalent than NV AMD in all age groups. While large drusen were present in more than 1% of those aged 40 through 49 years, no cases of AMD were found in any of the studies for white persons in this age group. Rates were similar between men and women (age-adjusted odds ratio [OR] for men=1.01; 95% confidence interval [CI], 0.81-1.25).
BLACK PERSONS
Pooled data for black persons were derived from 3 studies-the Barbados Eye Study, the Baltimore Eye Survey, and the Salisbury Eye Evaluation Project. Drusen prevalence was strongly age related, while the prevalence of AMD increased less dramatically with age ( Table 2) . Black women aged 50 through 54 years had a 0.68% preva lence of AMD, which increased to 1.47% for those aged 70 through 74 years and to 2.44% for those aged 80 years and older. Five individuals younger than 50 years (all cases of NV AMD from the Barbados Eye Study) were identified among the 1705 evaluated, even though drusen were present in more than 2% of those in this age range. Although women had higher rates of AMD than men, differences were not statistically significant (age-adjusted OR for men=0.64; 95% CI, 0.31-1.32).
PREVALENCE AND PREDICTED PREVALENCE
Applying age-, race/ethnicity-, and gender-specific rates to the US population as determined in the 2000 US Census, we estimate that 1.75 million individuals (1.47%; 95% CI, 1.38-1.55%; Table 3 ) have AMD, 1.22 million (1.02%; 95% CI, 0.93-1.11%; Table 4 ) have NV AMD in at least 1 eye, 973000 individuals (0.81%; 95% CI, 0.77-0.86%; Table 5 ) have GA in at least 1 eye, and 7.3 million individuals (6.12%; 95% CI, 5.93-6.31%; Table 6 ) have large drusen (ie, Ն125 µm in diameter) in either 1 or both eyes (approximately 50% of these individuals have bilateral large drusen). These numbers are estimated to increase substantially in the coming decades. The number of individuals in the United States with AMD is estimated to increase more than 50% from 1.75 million in 2000 to 2.95 million in 2020. Applying the age-, race/ ethnicity-, and gender-specific rates, Australia is estimated at present to have 130000 cases of AMD; Western Europe has 3.35 million cases of AMD. Applying the higher rates for the prevalence of large drusen found in the Beaver Dam Eye Study, we would expect an additional 6.4 million white individuals in the United States to have large drusen in either 1 or both eyes.
COMMENT
From pooled data from population-based eye diseases prevalence studies, we estimate that, at present, 1.75 million individuals in the United States have either GA or NV AMD in at least 1 eye. Approximately 7.3 million persons are es- Abbreviations: CI, confidence interval; NA, not applicable. *Estimates for the prevalence of advanced age-related macular degeneration in the total US population (based on the US Census 2000) include estimates for Hispanics and other races/ethnicities (ie, Asian, Native American, Alaska Native, Hawaiian and other Pacific Islander, and any other race/ethnicity) and those designating more than 1 race/ethnicity on the US Census 2000 form. These estimates were derived using the modeled age-and gender-specific rates for black participants. The age-and gender-specific estimates for the prevalence of advanced age-related macular degeneration (defined as having neovascular or geographic atrophy age-related macular degeneration in either eye) derived in this way are available at Web site: http://www.nei.nih.gov/eyedata/.
(REPRINTED) ARCH OPHTHALMOL / VOL 122, APR 2004 timated to have the early stages of AMD defined by large retinal drusen in at least 1 eye. Individuals with at least 1 druse of 125 µm or larger in diameter had a 5.8% risk of progressing to advanced AMD in the same eye over 5 years in the Beaver Dam Eye Study (Ronald Klein, MD, PhD, written communication, September 16, 2002) , indicating that they are, indeed, at high risk. Similar rates were recently published in the Rotterdam Study in which eyes with fewer than 10 drusen 125 µm or larger in diameter had a 5-year risk of GA of 2% and of NV AMD of 1%. Those with 10 drusen or more had a 14% risk for both GA and NV AMD. 20 We estimate that 2.95 million persons in the United States will have AMD in 2020. It is unknown what the effect of high-dose vitamin supplementation using a combination of zinc, beta-carotene, and vitamins C and E will be on these projected rates. 7 Age-related macular degneration is associated with severe reductions in quality of life as documented by clinical depression in almost one third of those who have this condition. 21 Among individuals who have vision loss from AMD, 60% report significant declines in their ability to participate in valued activities. 22 Greater access to and use of rehabilitative services for those with irretrievable vision loss will be needed as advanced AMD affects a growing number of older Americans.
The current research has several limitations. First, although this is a meta-analysis of population-based studies, none of the studies enrolled all eligible subjects. On average, about 20% of those eligible did not participate, which may cause bias in the estimates. Nonparticipants may include more individuals with known disease, as these persons may not see any benefit to participating. Conversely, nonparticipants may have had better ocular health and did not participate because they saw no value in receiving a free eye examination.
A second limitation is the lack of gradable photographs. The number of ungradable photographs was higher in the 3 studies of black persons. The cameras used were different in those studies. While this higher rate of ungradable photographs may be attributable to cataract, it is also possible that those with poor central vision were harder to image, which would have led to un- Abbreviations: CI, confidence interval; NA, not applicable. *Estimates for the prevalence of advanced age-related macular degeneration in the total US population (based on the US Census 2000) include estimates for Hispanics and other races/ethnicities (ie, Asian, Native American, Alaska Native, Hawaiian and other Pacific Islander, and any other race/ethnicity) and those designating more than 1 race/ethnicity on the US Census 2000 form. These estimates were derived using the modeled age-and gender-specific rates for black participants. The age-and gender-specific estimates for the prevalence of advanced age-related macular degeneration (defined as having neovascular or geographic atrophy age-related macular degeneration in either eye) derived in this way are available at Web site: http://www.nei.nih.gov/eyedata/.
derestimates in these populations. The Baltimore Eye Survey documented that those who were blind from AMD were less likely to have gradable photographs. 13 A third important limitation is the lack of data on other minority US populations. For black persons the data in the younger ages were limited, and the numbers studied in the older age ranges were not particularly large. To date there are few data that provide stable estimates of AMD prevalence in Hispanic persons. In the National Health and Examination Survey (NHANES) III, rates were based on 1 photograph of 1 eye of each subject. Agerelated macular degeneration was present in 0.5% of non-Hispanic white persons, 0.13% of non-Hispanic black persons, and 0.06% of Mexican Americans 40 years or older. 23 In the San Luis Valley Study, San Luis Valley, Colo, of the 571 Hispanic persons aged 43 through 74 years living in Colorado sampled for the study, the prevalence of early maculopathy (pigmentary changes and/or soft drusen) was 10%, slightly lower than that found for white persons (14%, PϽ.05), but AMD was found in only person. 24 Both of these studies suggest a low rate of AMD in Hispanic persons compared with white and black persons. Based on these articles, it is possible that our estimates of AMD in Hispanic persons and those of other races/ethnicities, which assume the same prevalence rates as black persons, may overestimate the number of individuals with AMD in these populations. However, a recent report from Arizona near the Mexican border found that AMD was the second leading cause of visual impairment in that Hispanic American population, indicating that we may have underestimated AMD prevalence in this population. 25 These estimates will need to be updated as prevalence surveys are published in these populations. Caution must be taken in using our data to compare rates between racial/ethnic groups.
Fourth, differential misclassification may affect the estimated rates of AMD in black persons. For example, it is possible that eyes with polypoidal choroidopathy may be incorrectly classified as NV AMD in black persons compared with white persons, a possible explanation for the higher rates in younger blacks compared with younger whites. Abbreviations: CI, confidence interval; NA, not applicable. *Estimates for the prevalence of advanced age-related macular degeneration in the total US population (based on the US Census 2000) include estimates for Hispanics and other races/ethnicities (ie, Asian, Native American, Alaska Native, Hawaiian and other Pacific Islander, and any other race/ethnicity) and those designating more than 1 race/ethnicity on the US Census 2000 form. These estimates were derived using the modeled age-and gender-specific rates for black participants. The age-and gender-specific estimates for the prevalence of advanced age-related macular degeneration (defined as having neovascular or geographic atrophy age-related macular degeneration in either eye) derived in this way are available at Web site: http://www.nei.nih.gov/eyedata/. mined effort to identify effective preventive strategies will be needed if we are to avoid a large increase in the numbers of persons having this condition.
